INTRODUCTION
 In Australia, submissions for drugs are lodged by sponsors and the Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Minister for Health on their listing on the national Pharmaceutical Benefits Schedule (PBS). Information on the outcomes of submissions to the PBAC is made public on the Department of Health and Ageing website, and further detail is provided in Public Summary Documents (PSDs). 7  The PBAC guidelines request that the submission present evidence of comparative clinical efficacy and safety as well as cost-effectiveness versus the treatment most likely to be replaced in practice. -the comparison was made using data from single-arm trials. These products were mainly confined to oncology and tended to have different methodological issues.
 If there were multiple submissions for the one product, these were treated as one submission unless there had been a clear change in the approach taken.
 Once the included dataset was confirmed, all PSDs for the drug, indication, and outcomes were reviewed noting the final recommendation, the comparator used as part of the indirect comparison, the clinical and economic claim, and any points of concern or uncertainty relating to the indirect comparison. RESULTS: PSDs relating to 105 products using an indirect comparison as the primary analysis were reviewed. A total of 70 (67%) submissions were recommended; the remaining submissions were rejected (32, 30%) or deferred (3, 3%). An indirect comparison was used to support a non-inferiority claim in 84 (80%) submissions and superiority claim in 21 (20%) submissions. Of those claiming non-inferiority, 60 (71%) submissions were recommended by the PBAC. Of those claiming superiority, the PBAC accepted the clinical claim for 10 (48%) submissions; 6 (29%) received a price premium. The PBAC expressed concerns relating to the indirect comparisons in 56 (53%) PSDs. The key issues related to the exchangeability of the trials as a consequence of different patient populations (25%), quality of trials (24%), and dosing (18%).
CONCLUSIONS:
Clinical comparisons based on indirect evidence are associated with increased uncertainty related to the exchangeability of the trials. The PBAC usually accepts evidence to support a claim of non-inferiority, but rarely the same in regards to superiority.
RESULTS

Dataset
 Of the 590 PSDs published between July 2005 to November 2012, 202 PSDs were identified from the initial "indirect comparison" search.
 After applying the exclusion criteria, the dataset comprised 122 PSDs. Some of these PSDs represented the same product for the same indication and were therefore counted as one submission resulting in 105 individual product submissions.
Outcomes
 Of the 105 individual product submissions, 70 (67%) were recommended; 32 (30%) rejected and 3 (3%) deferred (Figure 1 ).
 When the outcomes were examined by year, it appears that success rates were higher before 2008. With the exception of 2009, the rejection rate increased after 2008, the year of the release of the ICWG report.
Clinical Claim
Non-inferiority  The clinical claim was non-inferiority in 84 (80%) submissions. Of those claiming non-inferiority, 60 (71%) submissions were recommended by the PBAC.
Superiority
 The clinical claim was superiority in 21 (20%) of submissions. The PBAC accepted the clinical claim to some extent in 10 (48%) of cases.
 Despite recognition of a clinical advantage, the PBAC ultimately recommended listing on cost-effectiveness basis for 6 (29%; Table 1 ). In two of these submissions (infliximab and sunitinib), the common arm was considered of similar efficacy as the comparator, thus reducing the uncertainty of the analysis.
 In the four submissions where PBAC accepted the superiority claim to some extent, two were recommended on a cost minimisation basis due to uncertainty with the overall clinical evidence, and the remaining two were rejected based on an unacceptably high ICER and uncertainty in relation to the clinical claim.
Points of Concern
 Of the 34 submissions that were initially rejected, a variety of issues were raised, such as the wrong choice of comparator, high or uncertain ICER, and overall concern relating to the clinical claim and supporting evidence.
 Concerns regarding the appropriateness of the indirect comparison appeared to be an important issue for 9 (26%) submissions.
 The most commonly reported issues irrespective of the final recommendation were -differences in the patient population (25%). These differences were either due to different selection criteria and/or patient demographics.
-differences in the quality and method of trials (24%). These often related to differences in the definition or timing of outcome measures or differences in follow up.
-differences in circumstances of use (18%). These issues were primarily around dosing and the use of concomitant medications. 
